Peanut Allergy Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517534
  • Report
  • 88 pages
  • P&S Market Research
1 of 3
Peanut Allergy Therapeutics Pipeline in 2018

Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately 19 drug candidates in different stages of development.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of peanut allergy are being developed to be administered by the oral route which is convenient to take, and has been considered as non-invasive, and is often a safer route that requires no special training to be given to the patients.

Peanut Allergy Therapeutics Pipeline growth characterized by Various Technological Advancements

It has been observed that most of the companies are developing drug candidates by using advanced technologies and the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, BioLingus Inc. is utilizing its technology, BioLingus technology, which is a micro-encapsulation process, that delivers macro molecules such as peptides and proteins and is particularly effective for sublingual immunotherapy. With this technology, it has been observed in the Pre-Clinical models that sublingual IL-2 is found efficacious in 500th times lower amount than the investigational sublingual IL-2 therapy for the treatment of peanut allergy.

Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by industry participant by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Sign & Symptoms
4.3 Pathophysiology
4.4 Epidemiology
4.5 Diagnosis
4.6 Prevention and Treatment
4.7 Key Drivers
4.7.1 Rise in the Number of Patent Approvals
4.7.2 Driver 2
4.8 Key Barriers
4.8.1 Risks Involved in the Development of Drug Candidates
4.9 Peanut Allergy Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company

5. Peanut allergy Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase III
5.1.1 AR-101 Clinical trial Clinical results Designation Patent
5.1.2 XX Clinical trial Strategic development Technology
5.2 Phase II
5.2.1 XX Clinical trial Strategic development Patent Technology
5.3 Phase I
5.3.1 HAL-MPE1 Clinical trial Clinical result
5.3.2 XX Strategic development
5.3.3 XX Clinical trials Strategic development Technology Designation Patent Grant
5.3.4 XX
5.3.5 XX Strategic development Technology
5.3.6 XX Technology
5.4 Pre-Clinical
5.4.1 Low dose sublingual IL-2 (Project B7 (SLIT)) Technology
5.4.2 XX
5.4.3 XX Pre-Clinical results Clinical trials Technology
5.4.4 XX
5.4.5 XX Technology
5.4.6 XX Pre-Clinical studies
5.4.7 XX
5.5 Discovery
5.5.1 VTC-064 Strategic development
5.5.2 XX Strategic development Technology
5.5.3 XX Technology

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for Peanut Allergy Therapeutics Pipeline
7.2 SWOT Analysis of Peanut Allergy Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 AnaptysBio Inc.
8.1.1 Business Overview
8.1.2 Product and Service Offerings
8.2 Aimmune Therapeutics Inc.
8.2.1 Business Overview
8.2.2 Product and Service Offerings
8.3 Company 3
8.3.1 Business Overview
8.3.2 Product and Service Offerings
8.4 Company 4
8.4.1 Business Overview
8.4.2 Product and Service Offerings
8.5 Company 5
8.5.1 Business Overview
8.5.2 Product and Service Offerings
8.6 Company 6
8.6.1 Business Overview
8.6.2 Product and Service Offerings
8.7 Company 7
8.7.1 Business Overview
8.7.2 Product and Service Offerings
8.8 Company 8
8.8.1 Business Overview
8.8.2 Product and Service Offerings
8.9 Company 9
8.9.1 Business Overview
8.9.2 Product and Service Offerings
8.10 Company 10
8.10.1 Business Overview
8.10.2 Product Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Peanut Allergy Therapeutics, by Company (2018)
Table 2 Description of Ar-101
Table 3 Clinical Trials of Ar-101
Table 4 Description of Xx
Table 5 Clinical Trials of Xx
Table 6 Description of Xx
Table 7 Clinical Trials of Xx
Table 8 Description of Hal-Mpe1
Table 9 Clinical Trials of Hal-Mpe1
Table 10 Description of Xx
Table 11 Description of Xx
Table 12 Clinical Trials of Xx
Table 13 Description of Xx
Table 14 Description of Xx
Table 15 Description of Xx
Table 16 Description of Low Dose Sublingual Il-2 (Project B7 (Slit))
Table 17 Description of Xx
Table 18 Description of Xx
Table 19 Description of Xx
Table 20 Description of Xx
Table 21 Description of Xx
Table 22 Description of Xx
Table 23 Description of Vtc-064
Table 24 Description of Xx
Table 25 Description of Xx
Table 26 Anaptysbio Inc.- At a Glance
Table 27 Aimmune Therapeutics Inc. - At a Glance
Table 28 Company 3 - At a Glance
Table 29 Company 4 - At a Glance
Table 30 Company 5 - At a Glance
Table 31 Company 6 - At a Glance
Table 32 Company 7 - At a Glance
Table 33 Company 8 - At a Glance
Table 34 Company 9 - At a Glance
Table 35 Company 10 - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: Peanut Allergy Drug Candidates In Development (2018)
Fig 5: Peanut Allergy Pipeline Split, by Molecule Type (2018)
Fig 6: Peanut Allergy Pipeline Split, by Route of Administration (2018)
Fig 7: Breakdown of Clinical Trials, by Region
Fig 8: Breakdown of Clinical Trials, by Trial Status
Fig 9: Key Players Benchmarking
Fig 10: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown